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Abstract
Background: Helicobacter pylori antibiotic resistance is an increasing problem world-
wide. Pylera® may be an option as salvage therapy.
Aim: To assess the effectiveness, safety, and tolerance of Pylera® as a third- line in 
clinical practice.
Materials and Methods: This was a multicenter, observational, prospective database 
study in four Spanish hospitals. Consecutive H. pylori- infected individuals treated with 
Pylera® and a proton- pump inhibitor (PPI) were invited to participate if they had failed 
to respond to PPI- clarithromycin- amoxicillin as first- line and to levofloxacin- 
amoxicillin- PPI as second- line therapy. Eradication was tested 4- 8 weeks after Pylera® 
using a C13- urea breath test. Treatment- related adverse effects (TRAEs) were assessed 
through a questionnaire and by reviewing databases. A questionnaire on patient satis-
faction was completed in the last visit.
Results: Of 103 subjects fulfilling the selection criteria, 101 were included in the 
intention- to- treat (ITT) analysis and 97 in the per- protocol (PP) analysis. A 10 day 
course was prescribed in all patients. Esomeprazole 40 mg b.i.d. was the most used PPI 
regimen (ITT=94.1%). Ninety- seven individuals (ITT=96.04%) completed more than 
90% of the treatment. Overall eradication rates were ITT=80.2% (95% confidence in-
terval [CI]: 72.3%- 88.1%) and PP=84.4% (95% CI: 76.8%- 91.8%). One or more TRAEs 
were experienced by 67.3% (95% CI: 57.7%- 75.7%), all mild or moderate. TRAEs and 
the number of pills were the main complaints.
Conclusion: In an area of high antibiotic resistance to H. pylori, 10- day Pylera® plus 
double- dose PPI emerged as an alternative as third- line therapy, although not achiev-
ing optimal eradication rates. TRAEs were common but were neither severe nor did 
they condition compliance.
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1  | INTRODUCTION
Helicobacter pylori infection is a global health problem affecting more 
than a half of the world population.1,2 It is a well- established cause 
of chronic gastritis, peptic ulcer disease, MALT lymphoma, and gas-
tric adenocarcinoma, and its eradication cures or prevents most of 
these diseases.3 During the late twentieth and early twenty- first cen-
turies, clarithromycin- based triple therapy and levofloxacin regimens 
achieved high eradication rates in most countries. However, in parallel 
with the situation for other bacterial infections, antibiotic resistance 
has steadily increased and has become a significant challenge for na-
tional health systems and attending physicians.4,5 Specific point muta-
tions in the DNA of H. pylori caused by antibiotic misuse are the main 
molecular mechanism of drug resistance.6 Currently, clarithromycin 
resistance is highly prevalent in Western nations, and recent clinical 
practice guidelines no longer recommend the classic triple therapy 
as a first- line option (amoxicillin, clarithromycin, and a proton- pump 
inhibitor [PPI], [PPI- AC]), rather they favor the concomitant regimen 
(PPI- AC plus metronidazole).3,7,8 Levofloxacin- containing second- line 
rescue therapy has traditionally been one of the most used alternatives 
and was supported by the Maastricht IV/Florence consensus report 
published in 2012 and by our national guidelines.9,10 Nonetheless, H. 
pylori’s resistance to levofloxacin is on the rise due to fluoroquino-
lone overuse, and rates have been estimated at 22%- 33.9% in Europe, 
4.9%- 34.5% in Asia, and 31.9% in the United States accordingly to 
a recent study among male US Veterans.4,11 Thus, in the subgroup 
of patients refractory to first- and second- line treatment, bismuth- 
quadruple therapy (bismuth, metronidazole, tetracycline, and a PPI) 
is lately recommended, although available evidence supporting this 
approach is limited.3,7 This combination has several advantages: First, 
tetracycline resistance is rare (<1%) or even absent in some regions4; 
second, its effectiveness despite in vitro metronidazole resistance has 
been reported12,13; and third, it has been shown that bismuth tends to 
aggregate within and on the surface of H. pylori exerting an antibac-
terial effect.14 However, on the downside, tetracycline availability is 
highly variable in many countries, side effects are common, and adher-
ence to this bismuth- quadruple therapy is usually suboptimal.
In 2016, Pylera® (three- in- one capsules containing metronida-
zole 125 mg, bismuth subcitrate potassium 140 mg, and tetracycline 
125 mg) was marketed in many countries of southern Europe to fa-
cilitate posology, overcome shortage of tetracycline, and eventually 
improve eradication rates. However, the effectiveness of this spe-
cific formulation as third- line treatment in clinical practice is largely 
unknown.
The objective of this multicenter study was to ascertain the use-
fulness in a real- world scenario of quadruple therapy with this three- 
in- one formulation (Pylera®). Additionally, we determined the safety, 
compliance, and patient perception of Pylera®.
2  | METHODS
This was a prospective database, single- arm, observational study con-
ducted at four Spanish hospitals.
The study protocol adhered to the principles of the Declaration 
of Helsinki and was approved by the ethics committees for clinical 
research of the participating centers and by the Spanish Agency of 
Medicinal Products and Medical Devices. Signed informed consent 
was required for participation in the study.
2.1 | Study population and procedures
Patients over 18 years of age with H. pylori infection who were treated 
with Pylera® three capsules q.i.d and a PPI as third- line treatment 
were consecutively enrolled. In all patients, first- line treatment with 
PPI- AC and second- line treatment with levofloxacin, amoxicillin plus 
a PPI had failed. The inclusion period was March 2016 to December 
2016.
For inclusion, H. pylori infection had to have been documented 
by a C13- labeled urea breath test (UBT) in the year prior to treatment 
with Pylera®. Before the inclusion, H. pylori infection was reassessed 
with a new UBT in those patients with antibiotic usage after second- 
line therapy. Eradication was assessed through a UBT four to eight 
weeks after Pylera® administration. Consumption of antibiotics or 
PPIs 20 days before this test was an exclusion criterion.
In two centers (Hospital Universitario Ramón y Cajal de Madrid 
and Hospital Universitario de Salamanca), a patient satisfaction survey 
was performed in the last visit. All participants were followed from 
Pylera® prescription until the visit in which they were informed about 
eradication status and in which treatment- related adverse events 
(TRAEs) were assessed.
2.2 | Study endpoints
The primary endpoint was H. pylori eradication, defined as one 
negative13C- labeled UBT between 4 and 8 weeks after treatment. 
Secondary endpoints were safety, tolerance, compliance, predictors of 
eradication, and patient opinion in real clinical practice. Optimal compli-
ance was defined as taking at least 90% of the prescribed medications.
Treatment- related adverse events were classified as follows: mild 
when easily tolerated by the patient, did not require specific therapy 
or medication, and did not lead to treatment suspension; moderate 
when they limited routine activities or required specific therapy or 
medication; and severe when they required hospitalization, caused 
death, or were disabling for usual activities and required specific ther-
apy or medication. TRAEs were assessed in the last visit through a 
detailed questionnaire specifically designed for this study and by re-
viewing hospital and primary care electronic databases.
K E Y W O R D S
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Compliance was routinely assessed in the last visit during clinical 
interview by means of a specific questionnaire and recovery of empty 
medication envelopes of both Pylera® and PPI. In case of discordance, 
the lowest compliance was assumed. In cases where patients did not 
provide the blisters, results from the questionnaire were used.
2.3 | Statistical analysis
Data were analyzed separately for the intention- to- treat (ITT) anal-
ysis, which included all subjects prescribed Pylera®, and for the 
per- protocol (PP) population, which included all ITT subjects who 
completed the study without any events that could potentially bias 
the study outcome. 95% confidence intervals (CI) for eradication rates 
and TRAEs were calculated based on the Wilson method. The number 
of medical visits needed for treatment, including primary care visits, 
was registered. The UBT visit for eradication assessment was not in-
cluded in this variable.
Mean, standard deviation, median, and range were calculated 
for continuous variables and frequency counts and percentages for 
categorical data. The Mann- Whitney U test was used to compare 
continuous data. Chi- squared and Fisher’s exact tests were used for 
categorical data. All analyses were two- tailed, and P-values less than 
.05 were considered significant. Analyses were performed at the 
promoting institution (Hospital Universitario Ramón y Cajal, Madrid, 
Spain) using STATA software version 14.1 (Stata corp. Texas, CA, USA).
3  | RESULTS
One hundred and three patients met the inclusion criteria and none of 
the exclusion criteria, two individuals refused to participate, and three 
were lost to follow- up after Pylera® prescription. Thus, 101 patients 
were included in the ITT analysis and 97 in the PP analysis. Baseline 
demographic characteristics and indications for H. pylori treatment are 
summarized in Table 1. In all patients, treatment duration was 10 days. 
Esomeprazole 40 mg b.i.d was prescribed in 95 subjects (ITT=94.1%) 
and omeprazole 40 mg b.i.d. in six (ITT=5.9%). Compliance was op-
timal in 97 patients (ITT=96.04%) and only 60% in one patient. The 
overall eradication rate for the ITT population was 80.2% (95% CI: 
72.3% - 88.1%) and 84.4% (95% CI: 76.8% - 91.8%) for the PP partici-
pants; participating institutions did not show significant differences in 
this factor (Table 2). Neither were significant differences in eradication 
rates detected between those treated because of nonulcer dyspepsia 
(65 of 101, eradication rate ITT=83.1%, 95% CI: 72.2% - 90.3%) versus 
other indication (36 of 101 eradication rate ITT=75%, 95% CI: 58.9% - 
86.2%, P=.13); patients who were prescribed omeprazole (eradication 
rate ITT=83.3%, 95% CI: 43.6% - 97%) vs esomeprazole (eradication 
rate ITT=80%, 95% CI: 70.9% - 86.8%, P=1.0); or patients who were 
active smokers versus nonsmokers (P=.33). No predictors of eradica-
tion were found. Of 195 TRAEs recorded, 165 were mild (84.6%, 95% 
CI: 78.9% - 89%), 30 moderate, and none of them severe. Sixty- eight 
patients (67.3%, 95% CI: 57.7% - 75.7%) reported one or more TRAEs; 
dyspepsia and asthenia were the most common (Table 3). Ten patients 
were seen at the emergency department or by a general practitioner 
because of a TRAE. Headache was the final diagnosis in four patients, 
dyspepsia in three, mucosal candidiasis in two, and hypertensive 
crisis in one without complications who did not require hospitaliza-
tion or treatment suspension. Patients were followed for a median 
of 116 days after Pylera® prescription (range: 1- 192 days). A median 
of two medical visits (range 2- 5) was recorded between prescription 
and the visit in which the patient was informed about Pylera® success, 
both appointments inclusive. No clinically significant changes in vital 
signs or physical examination findings were documented.
The results of the patient’s opinion questionnaire about Pylera® 
completed by 78 participants are provided in Table 4.
TABLE  1 Baseline demographic and clinical characteristics 
(n=101)
Age 57.9 (14.1) years (mean, 
SD)
Female sex 75 (74.3%)




Diabetes mellitus 10 (9.9%)
Depression 15 (14.85%)
Ischemic cardiomyopathy 7 (6.9%)
Cirrhosis 1 (1%)
Previous gastrectomy 0
Active smoker 20 (19.8%)
Alcohol abuse 3 (2.9%)
Treatment indication
Nonulcerous dyspepsia 65 (64.4%)
Peptic ulcer disease 14 (13.9%)
Preneoplastic lesion 13 (12.9%)
First- degree relative(s) with gastric 
adenocarcinoma
6 (5.9%)
Iron deficiency anemia 3 (3%)
HRyC (n=45) HUSA (n=37) HUCA (n=10) HC (n=9)
ITT analysis 75.6% 86.5% 80% 77.7%
PP analysis 77.3% 86.5% 100% 88.8%
HRyC, Hospital Universitario Ramón y Cajal; HUSA, Hospital Universitario de Salamanca; HUCA, 
Hospital Universitario Central de Asturias; HC, Hospital de Cabueñes; ITT, Intention to treat; PP, 
Per- protocol.
TABLE  2 Eradication rates
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4  | DISCUSSION
Helicobacter pylori treatment failure is an ever- increasing reality 
worldwide. The development of effective, safe, and accessible res-
cue therapies is probably one of the major concerns with respect to 
this infection. In this multicenter real- life observational study, Pylera® 
gave rise to a limited overall eradication rate as third- line therapy in a 
common, well- defined refractory population (ITT=80.2%, PP=84.4%). 
According to recent guidelines, H. pylori eradication rates should be 
above 90%; consequently, these results should be categorized as 
poor. This arbitrary threshold is hardly achievable in real- world res-
cue therapies; in fact, the recent Maastricht V consensus recom-
mends third- line regimens with <80% of success.3 We consider that 
this study shows that Pylera®, although not obtaining ideal eradication 
rates, emerged as an alternative as a third- line regimen in an ever- 
increasing antibiotic resistance scenario.
To the best of our knowledge, this is the first study to specifically 
address its effectiveness after failure to respond to PPI- AC and a 
levofloxacin- amoxicillin regimen. Our findings are also the first data 
for Pylera® from Spain. In two phase III randomized clinical trials, one 
conducted in Europe and another in USA, improved ITT eradication 
rates over PPI- AC therapy were observed in naïve patients of 80% 
vs 55% and 87.7% vs 83.2%, respectively.13,15 In 2014, Delchier et al. 
performed an open- label, phase 3b, uncontrolled study in 49 patients 
who	had	 failed	 to	 respond	 to	≥1	 course	of	PPI-	AC	 therapy	with	or	
without up to three supplementary treatments. Pylera® plus omepra-
zole eradication rates were 93.2% to 93.8% in the ITT analysis and 
94.7% to 95% in the PP population.16 These better outcomes than in 
our participants could be explained by the interventional design of the 
trial including stricter selection criteria, a smaller sample size, and the 
inclusion of patients with only one failed regimen. Muller et al.12 (2016) 
conducted a prospective open- label study in 103 heterogeneous sub-
jects infected with a H. pylori strain resistant to clarithromycin, met-
ronidazole, and levofloxacin or individuals in whom multiple lines of 
treatment using these three antibiotics had failed. Their results resem-
ble our findings: an ITT eradication rate=83% (95% CI: 75%- 89%) and 
a PP eradication rate=87% (95% CI: 80%- 94%). Recently, Tursi et al.17 
(2017) described an initial encouraging Italian experience with Pylera® 
in a multicenter study in 131 patients, 76 having undergone previous 
eradication therapy. Eradication was recorded in 73 of these 76 pa-
tients (96.0%, 95% CI: 89%- 98.6%). However, it is important to remark 
that only 17 had been refractory to more than one regimen and more 
specific data were not available for this subgroup.
Other reports exist of bismuth- based quadruple therapy out 
of a three- in- one formulation as a third- line salvage regimen, and 
the results of the most relevant researches in the last decade are 
summarized in Table 5. The most representative in our area was a 
prospective, multicenter investigation with similar selection criteria 
to our study. ITT eradication was achieved in 65% (95% CI, 58%- 
72%), and PP eradication was 67% (95% CI, 60%- 74%). Although 
compliance (PP=97%) was comparable to that observed here, treat-
ment duration, PPI, doses of antibiotics, and bismuth were highly 
heterogeneous. This variability, besides geographic differences and 
the different composition of Pylera®- bismuth salt, could explain the 
lower eradication rates.18
TABLE  4 Patient questionnaire results (n=78)
Main drawbacks of treatment were as follows
Side effects 44 (56.4%)








Compared to previous treatments, compliance was as follows
More difficult 25 (25.4%)
Easier 18 (23.1%)
Similar 35 (44.9%)









Abdominal pain 25 (25.5%)
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As third- line treatment, rifabutin- containing regimens could be an 
alternative. In a systematic review, an overall eradication rate of 66% 
was provided for this option (95% CI, 55%- 77%).19 However, this anti-
biotic has major limitations of a potential risk of serious myelotoxicity, 
high cost, and concerns that its widespread use could lead to a rise in 
multidrug- resistant strains of M. tuberculosis.20
In our study, the PPI preferred by most clinicians was esomeprazole 
40 mg b.i.d over omeprazole 40 mg b.i.d. Esomeprazole is not included 
in the Pylera® European Medicines Agency data sheet, and recent 
guidelines do not unanimously support the benefits of last- generation 
or double- dose PPIs in all scenarios.3,7,8,21 This decision, although con-
troversial and not supported by head- to- head comparisons, could be 
explained by some data pointing to better overall eradication rates for 
triple therapies including new- generation PPIs.22,23 An important find-
ing of this study is that overall eradication rates remained suboptimal 
despite high- dose esomeprazole.
TABLE  5 Bismuth- quadruple therapy as a rescue treatment
Author
Number of 
patients Line Regimen Duration (days) ITT
Tursi, 201717 76 2nd- 3rd Pylera®
Omeprazole 20 mg b.i.d. 
Esomeprazole 40 mg b.i.d.
10 96%
Muller, 201612 103 2nd- 5th Pylera®
Omeprazole 20 mg b.i.d.
10 83%
Cao, 201529 143 2nd Lansoprazole 30 mg b.i.d 
B: 240 mg b.i.d. 
M: 400 mg q.i.d. 
T: 500 mg q.i.d.
14 88.1%
Gisbert, 201418 200 3rd PPI: standard 
dose b.i.d. 
B: 120 mg q.i.d. or 240 mg b.i.d. 
T: 250 mg t.i.d. to 500 mg q.i.d. 
M: 250 mg t.i.d. to 500 mg q.i.d.
7- 14 65%
Delchier, 201416 49 2nd- 4th Pylera®
Omeprazole 20 mg b.i.d.
10 93.2%
Yoon, 201230 169 2nd Pantoprazole 40 mg b.i.d. 
B: 300 mg q.i.d. 
M: 500 mg t.i.d. 





Chung, 201131 199 2nd Pantoprazole 40 mg b.i.d. 
B: 300 mg q.i.d. 
M: 500 mg t.i.d. 





Wu, 201132 62 2nd Esomeprazole 40 mg b.i.d. 
B: 120 mg q.i.d. 
T: 500 mg q.i.d. 
M: 250 mg q.i.d.
7 81%
Lee, 201133 45 3rd Omeprazole or Esomeprazole 20 mg b.i.d. 
B: 600 mg b.i.d. 
M: 500 mg b.i.d. 
T: 1 g b.i.d.
14 66.7%
Lee, 201034 112 2nd Esomeprazole 20 mg b.i.d 
B: 300 mg q.i.d. 
M 500 mg t.i.d. 





Usta, 200835 89 Omeprazole 20 mg s.i.d. 
B: 8 mg/kg/day 
M: 30 mg/kg/d 
D: 2 mg/kg/d
Omeprazole: 14 
B, M, D: 7
66.7%
Chung, 200736 87 2nd PPI b.i.d. 
B: 300 mg q.i.d. 
M: 500 mg t.i.d. 
T: 500 mg q.i.d.
7 84%
PPI, Proton- pump inhibitor; B, Bismuth; M, Metronidazole; T, Tetracycline; D, Doxycycline; ITT, Intention to treat.
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Optimal duration of therapy is another key question that remains 
unanswered. All our patients were treated for 10 days as Pylera® is 
licensed in this format. This could be seen as an important limita-
tion of this formulation as this duration is longer than necessary for 
metronidazole- susceptible and insufficient for metronidazole- resistant 
strains,7 what could partially explain our low eradication rates. The ben-
efits of empirically prolonging Pylera® to up to 14 days are not as well 
established as for PPI- AC combination therapy. Some studies have de-
tected a higher eradication rate with classic bismuth- quadruple ther-
apy when treatment is continued for at least two weeks.24 In contrast, 
a noninferiority clinical trial found no significant differences between 
10- and 14- day regimens despite increased costs.25 The results of a 
pilot study by Salazar et al.26 in 47 patients indicate that 14 days of 
Pylera® (PP eradication=97.1%, 95% CI: 86.3%- 99.9%) is more effec-
tive than a <10- day course (PP eradication=44.4%, 95% CI: 16%- 76%) 
when metronidazole resistance is suspected. Nonetheless, more rigor-
ous data are needed to determine the real efficiency of this approach.
Consistent with the available literature on Pylera©, TRAEs were 
frequent	(67.3%	showed	≥1)	though	in	all	cases	transient	and	mild	to	
moderate, also in line with literature data.12-17 The most frequent side 
effects were dyspepsia, asthenia, and dysgeusia. Ten patients sought 
medical attention due to TRAEs. Nonetheless, compliance (96.04%) 
was not hampered, and only one patient had to stop taking Pylera® 
after 7 days of treatment because of severe paresthesia, dysgeusia, 
and headache. The high adherence to treatment rate observed here 
could be attributable to patients under third- line being well- aware 
of H. pylori infection yet first- line interventional studies have also 
reported good compliance rates.13-15 Although this study was ob-
servational and resembling clinical practice, prospective designs may 
be at risk of Hawthorne bias; hence, a slight increase in adherence is 
possible.
Among the strengths of our study are that data were obtained 
from real- life practice and we also provide patient satisfaction data 
(Table 4). TRAEs and the number of pills were the main complaints. 
This is not surprising considering that the whole treatment course 
consists of 130- 140 capsules. Sporadic reports of severe TRAEs asso-
ciated with prolonged treatments have classically burdened bismuth- 
quadruple therapies.27 From our perspective, the present data lend 
support to an acceptable safety profile, suggesting the use of this 
medication should not be restricted for this concern.
This study has some limitations that should be acknowledged. (1) 
Its uncontrolled design prevents direct comparisons with other options, 
and although multicentric and involving different geographic areas, it 
was conducted in a single country. Spain has elevated clarithromycin 
(18%- 34%), levofloxacin (15%- 20%), and metronidazole (41%) resis-
tance rates7 such that we would predict similar results in populations 
with comparable antibiotic resistance profiles. (2) The study was un-
derpowered to detect predictors of eradication. (3) Our lack of anti-
biotic testing could be viewed as a weakness. However, microbiologic 
culture is not available in many centers and is rarely undertaken in 
clinical practice. Additionally, a recent review revealed no clear benefit 
of third- line susceptibility- guided treatment.28 Collectively, these find-
ings question the utility of culture in this context.8
In conclusion, our results provide evidence for Pylera® as a res-
cue regimen after PPI- AC and levofloxacin- amoxicillin triple therapy 
failure. Although common and unpleasant for patients, TRAEs were 
not severe and had no impact on compliance. In future studies, the 
benefits should be explored of a 14- day Pylera® course and alternative 
posology to help compliance and reduce TRAEs (eg, t.i.d instead of 
q.i.d or concomitant use of probiotics). Also, this formulation needs to 
be compared with other second- and third- line regimens, and the most 
efficient PPI regimen needs to be established.
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